Clinical Trial Detail

NCT ID NCT03828448
Title Study to Assess Umbralisib Plus Ublituximab in Patients With Treatment Naive Follicular Lymphoma
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors TG Therapeutics, Inc.
Indications

follicular lymphoma

CLL/SLL

Therapies

Ublituximab + Umbralisib

Age Groups: adult senior

No variant requirements are available.